

**Ceftolozane / Tazobactam Injection Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.2	14.04.2025	441427-00021	Date of first issue: 06.01.2016

**SECTION 1. IDENTIFICATION**

Product name : Ceftolozane / Tazobactam Injection Formulation

**Manufacturer or supplier's details**

Company : MSD

Address : 855 Leandro N. Alem St., 8 Floor  
Buenos Aires, Argentina C1001AFB

Telephone : 908-740-4000

Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

**Recommended use of the chemical and restrictions on use**

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

**SECTION 2. HAZARDS IDENTIFICATION****GHS Classification**

Respiratory sensitization : Category 1

Specific target organ toxicity - repeated exposure : Category 2 (Kidney, Liver)

Short-term (acute) aquatic hazard : Category 1

Long-term (chronic) aquatic hazard : Category 1

**GHS label elements**

Hazard pictograms :



Signal Word : Danger

Hazard Statements : H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled.  
H373 May cause damage to organs (Kidney, Liver) through prolonged or repeated exposure.  
H410 Very toxic to aquatic life with long lasting effects.

**Ceftolozane / Tazobactam Injection Formula-  
tion**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.2	14.04.2025	441427-00021	Date of first issue: 06.01.2016

Precautionary Statements : **Prevention:**  
P260 Do not breathe dust.  
P273 Avoid release to the environment.  
P284 Wear respiratory protection.

**Response:**  
P304 + P340 IF INHALED: Remove person to fresh air and keep comfortable for breathing.  
P342 + P311 If experiencing respiratory symptoms: Call a POISON CENTER/ doctor.  
P391 Collect spillage.

**Disposal:**  
P501 Dispose of contents/ container to an approved waste disposal plant.

**Other hazards which do not result in classification**

Dust contact with the eyes can lead to mechanical irritation.  
Contact with dust can cause mechanical irritation or drying of the skin.  
May form explosive dust-air mixture during processing, handling or other means.

**SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture : Mixture

**Components**

Chemical name	CAS-No.	Concentration (% w/w)
Ceftolozane	689293-68-3	>= 30 -< 50
Tazobactam	89786-04-9	>= 10 -< 20
Sodium chloride	7647-14-5	>= 10 -< 20

**SECTION 4. FIRST AID MEASURES**

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.  
If not breathing, give artificial respiration.  
If breathing is difficult, give oxygen.  
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.  
Get medical attention if symptoms occur.

In case of eye contact : If in eyes, rinse well with water.  
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention if symptoms occur.  
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and : Excessive exposure may aggravate preexisting asthma and other respiratory disorders (e.g. emphysema, bronchitis,

**Ceftolozane / Tazobactam Injection Formula-  
tion**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.2	14.04.2025	441427-00021	Date of first issue: 06.01.2016

delayed		reactive airways dysfunction syndrome). Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation. May cause allergy or asthma symptoms or breathing difficulties if inhaled. May cause damage to organs through prolonged or repeated exposure.
Protection of first-aiders	:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	:	Treat symptomatically and supportively.

**SECTION 5. FIRE-FIGHTING MEASURES**

Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO <sub>2</sub> ) Dry chemical
Unsuitable extinguishing media	:	None known.
Specific hazards during fire fighting	:	Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion products	:	Carbon oxides Metal oxides Chlorine compounds Nitrogen oxides (NO <sub>x</sub> )
Specific extinguishing methods	:	Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for fire-fighters	:	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

**SECTION 6. ACCIDENTAL RELEASE MEASURES**

Personal precautions, protective equipment and emergency procedures	:	Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages

**Ceftolozane / Tazobactam Injection Formula-  
tion**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.2	14.04.2025	441427-00021	Date of first issue: 06.01.2016

cannot be contained.

Methods and materials for containment and cleaning up : Surround spill with absorbents and place a damp covering over the area to minimize entry of the material into the air. Add excess liquid to allow the material to enter into solution. Soak up with inert absorbent material. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

**SECTION 7. HANDLING AND STORAGE**

Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not breathe dust. Do not swallow. Avoid contact with eyes. Avoid prolonged or repeated contact with skin. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Keep container tightly closed. Already sensitized individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respiratory irritants or sensitizers. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage : Keep in properly labeled containers. Keep tightly closed. Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types: Strong oxidizing agents

# Ceftolozane / Tazobactam Injection Formulation

Version 4.2      Revision Date: 14.04.2025      SDS Number: 441427-00021      Date of last issue: 30.09.2023  
Date of first issue: 06.01.2016

## SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

### Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Ceftolozane	689293-68-3	TWA	1000 µg/m <sup>3</sup> (OEB 1)	Internal
Further information: DSEN, RSEN				
		Wipe limit	100 µg/100 cm <sup>2</sup>	Internal
Tazobactam	89786-04-9	TWA	250 µg/m <sup>3</sup> (OEB 2)	Internal
Further information: RSEN				
		Wipe limit	100 µg/100 cm <sup>2</sup>	Internal

**Engineering measures** : Use feasible engineering controls to minimize exposure to compound.  
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

### Personal protective equipment

**Respiratory protection** : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

**Filter type** : Particulates type

**Hand protection** : Chemical-resistant gloves

**Material** : Chemical-resistant gloves

**Eye protection** : Wear safety glasses with side shields or goggles.  
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.  
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

**Skin and body protection** : Work uniform or laboratory coat.

**Hygiene measures** : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
When using do not eat, drink or smoke.  
Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

## SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

**Appearance** : powder

**Color** : No data available

**Ceftolozane / Tazobactam Injection Formula-  
tion**

Version 4.2	Revision Date: 14.04.2025	SDS Number: 441427-00021	Date of last issue: 30.09.2023 Date of first issue: 06.01.2016
----------------	------------------------------	-----------------------------	---

---

Odor	:	No data available
Odor Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	No data available
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	No data available
Relative vapor density	:	No data available
Relative density	:	No data available
Density	:	No data available
Solubility(ies) Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available

**Ceftolozane / Tazobactam Injection Formula-  
tion**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.2	14.04.2025	441427-00021	Date of first issue: 06.01.2016

Particle characteristics  
Particle size : No data available

**SECTION 10. STABILITY AND REACTIVITY**

Reactivity : Not classified as a reactivity hazard.  
Chemical stability : Stable under normal conditions.  
Possibility of hazardous reac- : May form explosive dust-air mixture during processing,  
tions handling or other means.  
Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.  
Avoid dust formation.

Incompatible materials : Oxidizing agents  
Hazardous decomposition : No hazardous decomposition products are known.  
products

**SECTION 11. TOXICOLOGICAL INFORMATION**

Information on likely routes of : Inhalation  
exposure Skin contact  
Ingestion  
Eye contact

**Acute toxicity**

Not classified based on available information.

**Product:**

Acute oral toxicity : Acute toxicity estimate: > 5.000 mg/kg  
Method: Calculation method

**Components:****Ceftolozane:**

Acute toxicity (other routes of : LD50 (Rat): > 2.000 mg/kg  
administration) Application Route: Intravenous

LD50 (Mouse): > 1.500 mg/kg  
Application Route: Intravenous

LD50 (Dog): > 2.000 mg/kg  
Application Route: Intravenous

**Tazobactam:**

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg

LD50 (Mouse): > 5.000 mg/kg

Acute toxicity (other routes of : LD50 (Rat): > 5.000 mg/kg  
administration) Application Route: Intravenous

**Ceftolozane / Tazobactam Injection Formula-  
tion**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.2	14.04.2025	441427-00021	Date of first issue: 06.01.2016

---

LD50 (Mouse): > 5.000 mg/kg  
Application Route: Intravenous

LD50 (Dog): > 5.000 mg/kg  
Application Route: Intravenous

**Sodium chloride:**

Acute oral toxicity : LD50 (Rat): 3.550 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 42 mg/l  
Exposure time: 1 h  
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 5.000 mg/kg

**Skin corrosion/irritation**

Not classified based on available information.

**Components:****Sodium chloride:**

Species : Rabbit  
Result : No skin irritation

**Serious eye damage/eye irritation**

Not classified based on available information.

**Components:****Sodium chloride:**

Species : Rabbit  
Result : No eye irritation

**Respiratory or skin sensitization****Skin sensitization**

Not classified based on available information.

**Respiratory sensitization**

May cause allergy or asthma symptoms or breathing difficulties if inhaled.

**Components:****Ceftolozane:**

Test Type : Maximization Test  
Species : Guinea pig  
Result : Sensitizer

**Tazobactam:**

Result : Sensitizer



**Ceftolozane / Tazobactam Injection Formula-  
tion**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.2	14.04.2025	441427-00021	Date of first issue: 06.01.2016

---

**Sodium chloride:**

Test Type	: Local lymph node assay (LLNA)
Routes of exposure	: Skin contact
Species	: Mouse
Result	: negative

**Germ cell mutagenicity**

Not classified based on available information.

**Components:****Ceftolozane:**

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative
	Test Type: Chromosome aberration test in vitro Result: negative
	Test Type: In vitro mammalian cell gene mutation test Result: positive
	Test Type: In vitro mammalian cell gene mutation test Result: negative
Genotoxicity in vivo	: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Result: negative
	Test Type: Unscheduled DNA synthesis (UDS) test with mammalian liver cells in vivo Species: Mouse Result: negative

**Tazobactam:**

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative
	Test Type: In vitro mammalian cell gene mutation test Test system: mouse lymphoma cells Result: positive
	Test Type: Chromosome aberration test in vitro Test system: Chinese hamster fibroblasts Result: negative
Genotoxicity in vivo	: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Intraperitoneal injection Result: negative

**Ceftolozane / Tazobactam Injection Formula-  
tion**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.2	14.04.2025	441427-00021	Date of first issue: 06.01.2016

---

Test Type: Unscheduled DNA synthesis (UDS) test with  
mammalian liver cells in vivo  
Species: Mouse  
Result: negative

**Sodium chloride:**

Genotoxicity in vitro

: Test Type: In vitro mammalian cell gene mutation test  
Result: positive

Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: Saccharomyces cerevisiae, gene mutation assay  
(in vitro)  
Result: positive

Test Type: DNA damage and repair, unscheduled DNA syn-  
thesis in mammalian cells (in vitro)  
Result: positive

Test Type: Chromosome aberration test in vitro  
Result: positive

Test Type: Chromosome aberration test in vitro  
Result: negative

Genotoxicity in vivo

: Test Type: In vivo micronucleus test  
Species: Mouse  
Application Route: Intraperitoneal injection  
Result: negative

Test Type: Mutagenicity (in vivo mammalian bone-marrow  
cytogenetic test, chromosomal analysis)  
Species: Rat  
Application Route: Intraperitoneal injection  
Result: positive

Germ cell mutagenicity -  
Assessment

: Weight of evidence does not support classification as a germ  
cell mutagen.

**Carcinogenicity**

Not classified based on available information.

**Components:****Sodium chloride:**

Species	: Rat
Application Route	: Ingestion
Exposure time	: 2 Years
Result	: negative

**Ceftolozane / Tazobactam Injection Formula-  
tion**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.2	14.04.2025	441427-00021	Date of first issue: 06.01.2016

**Reproductive toxicity**

Not classified based on available information.

**Components:****Ceftolozane:**

Effects on fertility	:	Test Type: Fertility/early embryonic development Species: Rat Application Route: Intravenous injection Fertility: NOAEL: 1.000 mg/kg body weight Result: No effects on fertility.
Effects on fetal development	:	Test Type: Embryo-fetal development Species: Mouse Application Route: Intravenous injection Developmental Toxicity: NOAEL: 2.000 mg/kg body weight Remarks: No significant adverse effects were reported  Test Type: Embryo-fetal development Species: Rat Application Route: Intravenous injection Developmental Toxicity: NOAEL: 1.000 mg/kg body weight Remarks: No significant adverse effects were reported

**Tazobactam:**

Effects on fertility	:	Test Type: Fertility/early embryonic development Species: Rat Application Route: Intraperitoneal injection Fertility: NOAEL: 640 mg/kg body weight
Effects on fetal development	:	Test Type: Embryo-fetal development Species: Rat Application Route: Intraperitoneal injection Developmental Toxicity: NOAEL: 40 mg/kg body weight Result: Effects on early embryonic development.  Test Type: Embryo-fetal development Species: Rat Application Route: Intravenous injection Developmental Toxicity: NOAEL: 3.000 mg/kg body weight Result: No effects on fetal development.

**STOT-single exposure**

Not classified based on available information.

**STOT-repeated exposure**

May cause damage to organs (Kidney, Liver) through prolonged or repeated exposure.

**Components:****Ceftolozane:**

Target Organs	:	Kidney
Assessment	:	May cause damage to organs through prolonged or repeated

**Ceftolozane / Tazobactam Injection Formula-  
tion**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.2	14.04.2025	441427-00021	Date of first issue: 06.01.2016

---

exposure.

**Tazobactam:**

Target Organs	:	Liver
Assessment	:	May cause damage to organs through prolonged or repeated exposure.

**Repeated dose toxicity****Components:****Ceftolozane:**

Species	:	Rat
NOAEL	:	1.000 mg/kg
Application Route	:	Intravenous
Exposure time	:	28 days
Target Organs	:	Kidney
Symptoms	:	No adverse effects.

Species	:	Dog
LOAEL	:	300 mg/kg
Exposure time	:	28 days
Target Organs	:	Kidney

**Tazobactam:**

Species	:	Rat
NOAEL	:	40 mg/kg
Application Route	:	Intraperitoneal
Exposure time	:	6 Months
Target Organs	:	Liver

Species	:	Dog
NOAEL	:	40 mg/kg
LOAEL	:	80 mg/kg
Application Route	:	Intraperitoneal
Exposure time	:	6 Months
Target Organs	:	Liver

**Sodium chloride:**

Species	:	Rat
LOAEL	:	2.533 mg/kg
Application Route	:	Ingestion
Exposure time	:	2 y

**Aspiration toxicity**

Not classified based on available information.

**Ceftolozane / Tazobactam Injection Formula-  
tion**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.2	14.04.2025	441427-00021	Date of first issue: 06.01.2016

**Experience with human exposure****Components:****Ceftolozane:**

Ingestion : Symptoms: Diarrhea, Fever, Headache, Nausea, Skin irritation, Gastrointestinal discomfort

**Tazobactam:**

Inhalation : Remarks: May cause allergy or asthma symptoms or breathing difficulties if inhaled.

**SECTION 12. ECOLOGICAL INFORMATION****Ecotoxicity****Components:****Ceftolozane:**

Toxicity to algae/aquatic plants : EC50 (Anabaena flos-aquae): 0,0401 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201

NOEC (Anabaena flos-aquae): 0,0018 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201

M-Factor (Acute aquatic toxicity) : 10

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 10 mg/l  
Exposure time: 32 d  
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 9,6 mg/l  
Exposure time: 21 d  
Method: OECD Test Guideline 211

M-Factor (Chronic aquatic toxicity) : 10

Toxicity to microorganisms : EC50: > 1.000 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209

NOEC: 560 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209

**Tazobactam:**

Toxicity to algae/aquatic plants : EC50 (Anabaena flos-aquae): 0,96 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201

**Ceftolozane / Tazobactam Injection Formula-  
tion**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.2	14.04.2025	441427-00021	Date of first issue: 06.01.2016

---

NOEC (Anabaena flos-aquae): 0,44 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201

M-Factor (Acute aquatic toxicity) : 1

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 10,6 mg/l  
Exposure time: 32 d  
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 9,6 mg/l  
Exposure time: 21 d  
Method: OECD Test Guideline 211

Toxicity to microorganisms : EC50: > 1.000 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209

NOEC: 1.000 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209

**Sodium chloride:**

Toxicity to fish : LC50 (Lepomis macrochirus (Bluegill sunfish)): 5.840 mg/l  
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 4.136 mg/l  
Exposure time: 48 h

Toxicity to algae/aquatic plants : EC50: > 2.000 mg/l  
Exposure time: 96 h

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 252 mg/l  
Exposure time: 33 d

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia pulex (Water flea)): 314 mg/l  
Exposure time: 21 d

Toxicity to microorganisms : EC10: > 1.000 mg/l

**Persistence and degradability****Components:****Ceftolozane:**

Biodegradability : Result: Not readily biodegradable.  
Method: OECD Test Guideline 301D

**Tazobactam:**

**Ceftolozane / Tazobactam Injection Formula-  
tion**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.2	14.04.2025	441427-00021	Date of first issue: 06.01.2016

Biodegradability : Result: Not readily biodegradable.  
Method: OECD Test Guideline 301D

**Bioaccumulative potential****Components:****Ceftolozane:**

Partition coefficient: n-octanol/water : log Pow: -0,21

**Tazobactam:**

Partition coefficient: n-octanol/water : log Pow: -0,63

**Mobility in soil****Components:****Ceftolozane:**

Distribution among environmental compartments : log Koc: 3,3  
Method: OECD Test Guideline 106

**Tazobactam:**

Distribution among environmental compartments : log Koc: 0,87

**Other adverse effects**

No data available

---

**SECTION 13. DISPOSAL CONSIDERATIONS****Disposal methods**

Waste from residues : Do not dispose of waste into sewer.  
Dispose of in accordance with local regulations.  
Contaminated packaging : Empty containers should be taken to an approved waste  
handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

---

**SECTION 14. TRANSPORT INFORMATION****International Regulations****UNRTDG**

UN number	:	UN 3077
Proper shipping name	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ceftolozane, Tazobactam)
Class	:	9
Packing group	:	III
Labels	:	9
Environmentally hazardous	:	yes

**Ceftolozane / Tazobactam Injection Formula-  
tion**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.2	14.04.2025	441427-00021	Date of first issue: 06.01.2016

**IATA-DGR**

UN/ID No.	: UN 3077
Proper shipping name	: Environmentally hazardous substance, solid, n.o.s. (Ceftolozane, Tazobactam)
Class	: 9
Packing group	: III
Labels	: Miscellaneous
Packing instruction (cargo aircraft)	: 956
Packing instruction (passenger aircraft)	: 956
Environmentally hazardous	: yes

**IMDG-Code**

UN number	: UN 3077
Proper shipping name	: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ceftolozane, Tazobactam)
Class	: 9
Packing group	: III
Labels	: 9
EmS Code	: F-A, S-F
Marine pollutant	: yes

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable for product as supplied.

**Special precautions for user**

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

**SECTION 15. REGULATORY INFORMATION****Safety, health and environmental regulations/legislation specific for the substance or mixture**

Argentina. Carcinogenic Substances and Agents Registry.	: Not applicable
---	------------------

Control of precursors and essential chemicals for the preparation of drugs.	: Not applicable
---	------------------

**The ingredients of this product are reported in the following inventories:**

AICS	: not determined
DSL	: not determined
IECSC	: not determined

**SECTION 16. OTHER INFORMATION**



**Ceftolozane / Tazobactam Injection Formula-  
tion**

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.2	14.04.2025	441427-00021	Date of first issue: 06.01.2016

Revision Date : 14.04.2025  
Date format : dd.mm.yyyy

**Further information**

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

**Full text of other abbreviations**

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECl - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

# SAFETY DATA SHEET



## Ceftolozane / Tazobactam Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.2	14.04.2025	441427-00021	Date of first issue: 06.01.2016

---

AR / Z8